Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Arixa Pharmaceuticals

Arixa Pharmaceuticals is developing oral antibiotics for resistant Gram-negative infections, an urgent need. The company's lead candidate, ARX-1796, is a proprietary orally available prodrug of Avibactam, a broad spectrum beta-lactamase inhibitor recently approved by the FDA. The company's technology platform applies unique prodrug chemistry to existing intravenous-only antimicrobial agents to allow their active ingredients to be orally administered. ARX-1796 is anticipated to enter Phase 1 clinical testing in 2019.

Key Contact
Name
John Freund, MD
Title
CEO & Co-Founder
Funding Events

Date
Amount
Type
Investors
Valuation
05/01/18 $8,000,000 Seed


Featured Reading